MedTrace Logo

The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of Age in Jordan

NCT05562817 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2022-12-15

No results posted yet for this study

Summary

RSV has a global healthcare burden and vaccine in the main preventive measure. There are no recent published studies that have evaluated the burden of RSV infections in the Middle East in term of incidence at a national level, complication rates, mortality rates, hospitalizations, secondary infections, or the direct and indirect costs. Most studies have been limited to identifying genotypes or calculating the incidence in selected sites. In order to facilitate the introduction of an effective preventive measure for control of RSV infections, it is essential at a national and regional levels to assess the burden of disease, molecular epidemiology, and economic burden based on direct and indirect costs of RSV infections.

Conditions

  • Respiratory Syncytial Virus Infections

Sponsors & Collaborators

Eligibility

Min Age
0 Months
Max Age
60 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-20
Primary Completion
2023-06-30
Completion
2023-08-31

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05562817 on ClinicalTrials.gov